---
search:
  boost: 2 
---

# Alzheimerâ€™s Agents

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred                                | Generic Name                                           | Quantity | Time (Days) |
| :--------------------------------------- | :----------------------------------------------------- | :------: | :---------: |
| Donepezil 5mg, 10mg Tab <sup>AR QL</sup> | Donepezil Hydrochloride Tab (all strengths excl 23 MG) |   102    |     102     |
| Donepezil ODT <sup>AR QL</sup>           | Donepezil Hydrochloride ODT (all strengths)            |   102    |     102     |
| Exelon Patch <sup>AR BvG</sup>           |                                                        |          |             |
| Galantamine IR Tab <sup>AR QL</sup>      | Galantamin Hydrobromide Tab (all strengths)            |   204    |     102     |
| Galantamine ER Cap <sup>AR QL</sup>      | Galantamine Hydrobromide ER Cap (all strengths)        |   102    |     102     |
| Memantine Tab <sup>AR</sup>              |                                                        |          |             |
| Rivastigmine Cap <sup>AR QL</sup>        | Rivastigmine Tartrate Cap (all strengths)              |   204    |     102     |

### Non-Preferred

| Non-Preferred                       | Generic Name                                         |         Quantity          |        Time (Days)        |
| :---------------------------------- | :--------------------------------------------------- | :-----------------------: | :-----------------------: |
| Adlarity <sup>AR</sup>              |                                                      |                           |                           |
| Donepezil 23mg Tab <sup>AR QL</sup> | Donepezil Hydrochloride Tab 23 MG                    | Determined pursuant to PA | Determined pursuant to PA |
| Galantamine Sol <sup>AR QL</sup>    | Galantamine Hydrobromide Oral Soln (all strengths)   | Determined pursuant to PA | Determined pursuant to PA |
| Memantine ER <sup>AR</sup>          |                                                      |                           |                           |
| Memantine Sol <sup>AR</sup>         |                                                      |                           |                           |
| Namzaric <sup>AR</sup>              | Memantine HCI / Donepezil HCI ER Cap (all strengths) | Determined pursuant to PA | Determined pursuant to PA |
| Rivastigmine Patch <sup>AR</sup>    |                                                      |                           |                           |

## Authorizations

**Length of Authorizations**: 365 Days

### Grandfathering

Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug previously but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**AR** - All drugs: a PA is required for patients younger than 40 years

## Links


[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=25)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=13)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
